Inspira Outlines Strategic Vision and Transaction Framework for Breast Cancer Liquid Biopsy Expansion
RA'ANANA, Israel, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ:IINN) ("Inspira," "Inspira Technologies," or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today outlines its strategic vision and proposed transaction framework for its planned expansion into liquid biopsy diagnostics, outlining a structured approach designed to preserve shareholder value while enabling future dividend distributions the Company's core respiratory and life-support technologies. This framework underpins a proposed acquisition of an advanced liquid biopsy platform alongside a concurrent equity investment (the "Equity Investment"), positioning
